Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Tiziana Life Sciences PLC    TILS   GB00BKWNZY55

TIZIANA LIFE SCIENCES PLC

(TILS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Tiziana Life Sciences PL :  ("Tiziana" or the "Company") - PDMR Dealing

11/18/2020 | 10:16am EST

LONDON and NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 45,000 ordinary shares of 3p each in the market at a price of 84p per share.

The acquisition takes Mr Cerrone's interests from 34.029% to 34.052% (within the 1% incremental threshold under Note 11 to Rule 9 of the UK Takeover Code).

1.Details of PDMR / person closely associated
a)Name

Gabriele Cerrone
2.Reason for the notification

a)Position / status

Executive Chairman
b)Initial notification /amendment

Initial notification
3.Details of the issuer

a)Name

Tiziana Life Sciences plc
b)LEI

213800CED47HI8PIOB36
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type  of transaction; (iii) each date; and (iv) each place where transactions have  been conducted
a)Description of the financial instrument

Ordinary Shares of 3p each
b)Identification code of the Financial Instrument

ISIN for Tiziana Life Sciences plc: GB00BKWNZY55
c)Nature of the transaction

Market Purchase
d)Price(s) and volume(s)84p

45,000
f)Date of the transaction

18 November 2020
g)Place of the transaction

XLON  

About Tiziana Life Sciences

Tiziana Life Sciences plc is a dual listed (NASDAQ: TLSA & UK AIMS: TILS) biotechnology company that focuses on the discovery and development of novel molecules to treat human diseases in oncology, inflammation and infectious diseases. In addition to milciclib, the Company will be shortly initiating phase 2 studies with orally administered foralumab for Crohn’s Disease and nasally administered foralumab for progressive multiple sclerosis. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) in clinical development in the world. This phase II compound has potential application in a wide range of autoimmune and inflammatory diseases, such as Crohn’s Disease, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. The person who arranged the release of this information is Keeren Shah, Finance Director of Tiziana.

For further enquiries:

United Kingdom Investors:

Tiziana Life Sciences plc
Gabriele Cerrone, Chairman and founder
 +44 (0)20 7495 2379
   
Cairn Financial Advisers LLP (Nominated Adviser)
Liam Murray / Jo Turner
 +44 (0)20 7213 0880
   
Optiva Securities Limited (Broker)
Robert Emmet
 + 44 (0)20 3981 4173
   

United States Investors:

Dave Gentry
RedChip Companies Inc.
 Office 1 800 RED CHIP (733 2447)
Cell 407-491-4498 (USA)
dave@redchip.com

 


© OMX, source OMX

All news about TIZIANA LIFE SCIENCES PLC
01/20TIZIANA LIFE SCIENCES : Shares Soar Ahead of Listing on LSE Main Market
MT
01/20Tiziana Life Sciences to Participate in a Fireside Chat at B. Riley Virtual O..
GL
01/20TIZIANA LIFE SCIENCES : to Start Trading on LSE's Main Market Following AIM Deli..
MT
01/20Tiziana Life Sciences plc ("Tiziana" or the "Company") - AIM Delisting and Ad..
GL
01/13TIZIANA LIFE SCIENCES : Names Chief Medical Officer
MT
01/13TIZIANA LIFE SCIENCES : Science Appoints New Chief Medial Officer; Shares Up 13%
MT
01/13Tiziana announces appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medica..
GL
01/11Tiziana Life Sciences to participate at J.P. Morgan Healthcare Conference 202..
GL
01/11Tiziana Life Sciences to Present at Biotech Showcase Digital 2021
GL
01/07OKYO PHARMA : Gains 5% on Chair, CEO Appointment
MT
More news
Financials
Sales 2020 - - -
Net income 2020 - - -
Net Debt 2020 - - -
P/E ratio 2020 -
Yield 2020 -
Capitalization 313 M 428 M 429 M
Capi. / Sales 2020 -
Capi. / Sales 2021 -
Nbr of Employees 8
Free-Float 49,7%
Chart TIZIANA LIFE SCIENCES PLC
Duration : Period :
Tiziana Life Sciences PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TIZIANA LIFE SCIENCES PLC
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 844,35 GBX
Last Close Price 161,00 GBX
Spread / Highest target 583%
Spread / Average Target 424%
Spread / Lowest Target 266%
Managers and Directors
NameTitle
Kunwar Shailubhai CEO, Executive Director & Chief Scientific Officer
Gabriele Marco Antonio Cerrone Executive Chairman
Tiziano Lazzaretti Chief Financial Officer
Jules S. Jacob Senior Director-Non-Clinical Development
Vaseem A. Palejwala Director-Clinical Operations
Sector and Competitors
1st jan.Capitalization (M$)
TIZIANA LIFE SCIENCES PLC75.96%428
MODERNA, INC.25.41%51 846
LONZA GROUP AG5.34%50 271
CELLTRION, INC.-13.65%38 245
IQVIA HOLDINGS INC.3.58%35 582
SEAGEN INC.4.35%33 059